Kathleen P. Rubinstein

Healthcare Policy Analyst

Houston
T 713.276.1650  |  F 713.751.1717

Kathleen P. Rubinstein is a policy analyst who partners with the Healthcare Industry and Public Policy Teams on developing and implementing strategies for achieving client policy goals and resolving their regulatory concerns. Her professional focus centers on matters involving healthcare policy including regulation under the Medicare and Medicaid programs and implementation of the Affordable Care Act.

Kathleen writes extensively on healthcare industry issues and frequently collaborates with the Healthcare Industry and Public Policy Teams on articles and presentations of topical interest. She is the Editor of the BakerHostetler Health Law Update newsletter and blog. A long time instructor at the University of Houston, Kathleen teaches a graduate seminar on healthcare policy for students of public administration, political science and the law.

Select Experience

  • Works collaboratively on developing policy recommendations and legislative proposals; formulating strategic and tactical work plans and crafting communications strategies.
  • Plans and directs the work of stakeholder advisory groups in formulating solutions to complex policy problems.
More »

Experience

  • Works collaboratively on developing policy recommendations and legislative proposals; formulating strategic and tactical work plans and crafting communications strategies.
  • Plans and directs the work of stakeholder advisory groups in formulating solutions to complex policy problems.
  • Engages in research and analysis of existing and emerging policy topics; serves as an information resource on healthcare industry issues, developments and trends. 
  • Monitors, analyzes and assesses the impact of federal and state actions, legislation and rulemaking and emerging initiatives and proposals.
  • Participates in governmental policy and regulatory interactions at state and federal levels; prepares and manages government filings and submissions.

Recognitions

  • Recognition Award, University of Houston Masters of Public Administration Program 
  • List of Outstanding Graduates, National Association of Schools Public Affairs and Administration

Memberships

  • American Hospital Association
  • American Health Lawyers Association
  • University of Houston MPA Program Alumni Network

Services

Industries

Emerging Issues

Admissions

  • [Not an Attorney]

Education

  • M.A., Public Administration, concentration in Health Policy Studies, University of Houston, 1996
  • B.A., Our Lady of the Lake University, 1992, with honors

Blog

In The Blogs

Previous Next
Health Law Update
The ACA Five Years Later: A Good Investment or Risky Business? We Dare Not Opine!
March 27, 2015
The enactment of the Patient Protection and Affordable Care Act (ACA), signed into law on March 23, 2010, represents a significant legislative milestone in healthcare reform and a continuing communications challenge for providers. As we...
Read More ->
Health Law Update
FDA Establishes Docket for Public Comments on Drug Compounding
March 19, 2015
The Food and Drug Administration (FDA) recently announced a new docket for public comments on the compounding of human drug products under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FFDCA). The FDA hopes that these...
Read More ->
Health Law Update
State Health Regulatory Bodies Have Teeth Pulled
March 17, 2015
Old and new regulations established by state professional boards that are composed of “active market participants” such as physicians, dentists and therapists, may be subject to antitrust challenge following the U.S. Supreme Court’s recent...
Read More ->
Health Law Update
My Day at the U.S. Supreme Court: King v. Burwell
March 13, 2015
Describing her recent Supreme Court experience as “my Super Bowl,” Susan Feigin Harris offers her personal account and analysis of the oral arguments in King v. Burwell. I was ready to go: hat, gloves, boots and parka. A legal pad and two...
Read More ->
Health Law Update
FDA Issues Draft Memorandum of Understanding for 503A Drug Compounding
March 10, 2015
Included in the flurry of guidance documents recently issued by the FDA concerning human drug compounding is a long-awaited document of great importance to mail-order pharmacy compounders and entities that rely on interstate distribution...
Read More ->